*Department of Ophthalmology, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel;
†Department of Obstetrics and Gynecology, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel;
‡Center for Applied Biotechnology and Molecular Medicine (CABMM), University of Zurich, Zurich, Switzerland;
§ELZA Institute, Dietikon, Zurich, Switzerland;
¶Faculty of Medicine, University of Geneva, Geneva, Switzerland; and
‖Department of Ophthalmology, USC Roski Eye Institute, USC Los Angeles, Los Angeles.
Correspondence: Yonit Krakauer, MD, Department of Ophthalmology, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva 84965, Israel (e-mail: [email protected]).
F. Hafezi is the chief scientific and medical officer of EMAGine AG (Zug, Switzerland) and a coinventor of the PCT/CH2012/000090 application regarding CXL technology. The remaining authors have no financial or proprietary interest in the materials presented herein.
B. Knyazer and Y. Krakauer have contributed equally to this study
